University of Rochester Intellectual and Developmental Disabilities Research Center

摘要 学龄儿童智力和发育障碍(IDD)面临严重新冠肺炎的严重风险。 许多人免疫和呼吸功能受损，认知障碍和复杂的内科疾病 问题。患有IDD的孩子迫切需要上专门的学校，但这也使他们处于超高水平 尽管工作人员戴着面具、保持距离并接种了疫苗，但仍存在接触新冠肺炎和感染的风险。关键的是，我们 缺乏儿童新冠肺炎抗体免疫发展和持久性的纵向数据 和IDD专门学校的工作人员，包括跨菌株保护，以指导疫苗接种和发展 政策建议。本副刊汇集了罗切斯特大学的优势 智力和发育障碍中心和UR RADX-UP。在本管理下 补充，我们建议继续我们对抗SARS-CoV-2抗体的前瞻性、纵向跟踪 超过56名IDD学生和282名工作人员在一所为IDD儿童开设的专门学校工作。通过RADx-UP，我们目前有 每名受试者每月7份毛细血管血样分析抗尖峰抗体(S)和抗核蛋白(N)免疫球蛋白 测量SARS-CoV-2及其变异株和常见冠状病毒株(HCoV：OC43、HKU1、NL63、229E) 通过mPLEX-CoV研究试验。我们将延长这项前瞻性的纵向研究，再增加12项 几个月的采样捕获SARS-CoV-2抗体水平有升有降。在目标1中，我们将使用 多维测量抗SARS-CoV-2和其他冠状病毒抗体一年来的估计 接种疫苗和感染后抗体下降的速度。我们将利用记忆B细胞研究来 估计长寿命免疫记忆和抗SARS-Ig G免疫谱系的多维分析 冠状病毒2型变种。在目标2中，我们将把这些数据与全面的免疫反应基因型别和IDD联系起来 表型分析。疫苗反应基因的定向重新测序将提供关键信息 神经性和非典型人群免疫反应相关基因突变(如细胞因子启动子多态性) IDD儿童及其对SARS-CoV-2抗体水平的影响。本项目圆满完成 将确定接种疫苗的受试者中抗SARS-CoV-2抗体的衰减率，并提供有关关联的新数据 IDD表型和免疫基因SNPs与疫苗反应的关系。

ABSTRACT School-children with intellectual and developmental disabilities (IDD) are at acute risk for severe COVID-19. Many have compromised immunological and respiratory function, cognitive impairment and complex medical issues. Children with IDD desperately need to attend specialized schools, but this also places them at ultra-high risk of COVID-19 exposure and infection, despite masking, distancing, and vaccination of staff. Critically, we lack longitudinal data on development and persistence of antibody-mediated immunity to COVID-19 for children and staff in IDD-specialized schools, including cross-strain protection, to guide development of vaccination and policy recommendations. This supplement brings together the strengths of the University of Rochester Intellectual and Developmental Disabilities Center and the UR RADx-UP. Under this Administrative Supplement, we propose continuation of our prospective, longitudinal tracking of anti-SARS-CoV-2 antibodies in over 56 IDD students and 282 staff at a specialized school for IDD children. Via RADx-UP, we currently have 7 monthly capillary blood samples per subject analyzed for anti-spike (S) and anti-nucleoprotein (N) IgG against SARS-CoV-2 and variants, and common coronavirus strains (HCoVs: OC43, HKU1, NL63, 229E) measured by the mPLEX-CoV research assay. We will extend this prospective, longitudinal study with an additional 12 months of sampling to capture increases and decreases in SARS-CoV-2 antibody levels. In Aim 1 we will use multidimensional measurement of anti-SARS-CoV-2 and other coronavirus antibodies over 1 year to estimate the rate at which antibodies decrease after vaccination and infection. We will use memory B cell studies to estimate long-lived immune memory and multidimensional analysis of IgG immune repertoire against SARS- CoV-2 variants. In Aim 2, we will link these data, with a comprehensive immune response genotypic and IDD phenotypic analysis. Targeted resequencing of vaccine response genes will provide critical information on immune response associated gene mutations (e.g. cytokine promoter polymorphisms) in neurotypical staff and IDD children, and their influence on anti-SARS-CoV-2 antibody levels. Successful completion of this project will identify decay rates of anti-SARS-CoV-2 IgG in vaccinated subjects, and provide new data on association of IDD phenotyping and immune gene SNPs with vaccine responses.